Disarming carbapenemase-producing Acinetobacter baumannii : high potency of the novel therapeutic combination of meropenem and the innovative diazabicyclooctane β-lactamase inhibitor pilabactam (formerly ANT3310)
Open Access
- 1 April 2026
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (4) , e0169125
Abstract
Carbapenem-resistant Acinetobacter baumannii (CRAB) represents an urgent global health threat, with resistance primarily driven by carbapenem-hydrolyzing class D β-lactamases (CHDLs) such as OXA-23. Therapeutic options remain limited due to the scarcity of effective β-lactam/β-lactamase inhibitor combinations. Pilabactam (formerly ANT3310) is a novel diazabicyclooctane (DBO) β-lactamase inhibitor featuring a fluorine substituent that extends its activity spectrum, relative to approved DBOs like avibactam and relebactam, to include CHDLs. Pilabactam is currently in phase I clinical trials in combination with meropenem, and its activity and mechanism against CRAB remain incompletely defined. Using engineered A. baumannii strains producing individual β-lactamases, we show that pilabactam restores meropenem activity against serine β-lactamase producers, including difficult-to-inhibit CHDLs. This was corroborated in 68 whole-genome-sequenced meropenem-resistant clinical isolates, yielding MIC₅₀ and MIC₉₀ values for meropenem/pilabactam of 1 and 2 mg/L, respectively. Frequency of resistance studies in representative CHDL producers demonstrated suppression of resistance selection at 4× MIC. Kinetic analyses revealed that pilabactam inhibits OXA-23 via a two-step tight binding mechanism, with slightly higher inactivation rates (1.7 × 10⁴ M⁻¹s⁻¹) than that of durlobactam (3.5 × 10³ M⁻¹s⁻¹). Pilabactam also yielded a low dissociation constant ( K d ≈ 4 nM) and slow off-rate, indicating durable inhibition. Molecular dynamics simulations revealed the critical role of the fluorine substituent in forming stabilizing hydrogen-bonding and CH–F interactions within the tunnel-like OXA-23 active site. These findings identify pilabactam as a potent novel DBO supporting its development with meropenem for treating CRAB infections.Keywords
Funding Information
- Instituto de Salud Carlos III (PI23/00851)
- Xunta de Galicia (ED431C 2025/05)
- Centro Singular de Investigación de Galicia (ED431G 2023/03)
- Instituto de Salud Carlos III (CM23/00104)
- Xunta de Galicia (IN606A 2023/023)
- Instituto de Salud Carlos III (FI23/00074)
- Xunta de Galicia (IN606A 2024/033)
- Instituto de Salud Carlos III (CM23/00095)
- Instituto de Salud Carlos III (IN606B 2022/009)
- Instituto de Salud Carlos III (JR21/00026)
- Italian Ministry of University and Research and the European Union (B63C22001400007)
- Instituto de Salud Carlos III (PI22/01212)
- Instituto de Salud Carlos III (PI21/00704)
- Instituto de Salud Carlos III (PI20/01212)
- Instituto de Salud Carlos III (CB21/13/00055)
- Xunta de Galicia (IN607D 2021/12)
- Xunta de Galicia (IN607D 2024/08)
- Xunta de Galicia (IN607A 2024/09)
- Agencia Estatal de Investigación (PID2022-136963OB-I00/AEI/10.13039/501100011033)
This publication has 51 references indexed in Scilit:
- Multidrug-resistant Gram-negative bacterial infectionsThe Lancet, 2025
- Siderophores: Chemical tools for precise antibiotic deliveryBioorganic & Medicinal Chemistry Letters, 2023
- In vitro and in vivo activities of a novel β-lactamase inhibitor combination imipenem/XNW4107 against recent clinical Gram-negative bacilli from ChinaJournal of Global Antimicrobial Resistance, 2022
- In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistanceJournal of Global Antimicrobial Resistance, 2022
- 6-Halopyridylmethylidene Penicillin-Based Sulfones Efficiently Inactivate the Natural Resistance of Pseudomonas aeruginosa to β-Lactam AntibioticsJournal of Medicinal Chemistry, 2021
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trialThe Lancet Infectious Diseases, 2021
- Discovery of ANT3310, a Novel Broad-Spectrum Serine β-Lactamase Inhibitor of the Diazabicyclooctane Class, Which Strongly Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacterales and Acinetobacter baumanniiJournal of Medicinal Chemistry, 2020
- ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SBJournal of Chemical Theory and Computation, 2015
- Structural Basis for Carbapenemase Activity of the OXA-23 β-Lactamase from Acinetobacter baumanniiChemistry & Biology, 2013
- Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. CohenJournal of Molecular Biology, 1997